Home › NDC Lookup › Ingredients › Nystatin › 45802-0048-11
🧴image loading
(from DailyMed)

Nystatin 100000 [USP'U]/g Ointment — NDC 45802-048-11 (Billing 45802-0048-11)

by Padagis Israel Pharmaceuticals Ltd · 1 TUBE in 1 CARTON / 30 g in 1 TUBE

This is a package of Nystatin 100000 [USP'U]/g Ointment from Padagis Israel Pharmaceuticals Ltd, marketed since Sep 2006 and currently FDA-listed; retail pharmacies pay about $0.2375 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 45802-0048-11
🏷️ FDA NDC (as labeled) 45802-048-11 billing pads the product segment with a zero
This package
Contains30 g in 1 tube Cost per g$0.2375 NADAC Per package$7.13 / 30 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.4813/unit · Part D plans $0.4011/unit — full pricing hub ↓
Main listing for product 45802-048 · Also comes in: 15 g 45802-048-35
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Nystatin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 23, 2026 — Subpotent Drug: Low out of specification assay results performed during long-term stability testing. (Padagis US LLC) · FDA recall D-0677-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-048-11
Product NDC 45802-048
11-digit billing NDC 45802004811
NCPDP billing unit GM — per gram (weight)
RxCUI 884308
UNII BDF1O1C72E
Application # ANDA062472
SPL Set ID 6c091c66-2e4d-4412-b7bf-35315dc8152f
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-09-15
Route TOPICAL
Dosage form OINTMENT
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080004215
GPI class Nystatin
GCN Seq No 007283
GCN 30150
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYSTATIN 100,000 UNIT/GM OINT
FDB brand name Nystatin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007283
  • GCN: 30150
  • GPI-14 (Medi-Span): 90150080004215
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 884308
Why two NDCs? The FDA registers this code as 45802-048-11 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0048-11. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYSTATIN 100,000 UNIT/GM OINT Ingredient Nystatin
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.238 $7.13 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.4813 $14.44 / 30 g
Medicare drug plans payPart D · Q2 2026 $0.4011 $12.03 / 30 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.314 $0.238
▼ Down 16% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0048-11 You're viewing this Main listing 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.2375 / g $7.13 2006-11-08 — Active
45802-0048-35 45802-048-35 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.2331 / g $3.50 2006-09-15 — Active

In Medicaid, this is the most-dispensed pack of this product — about 60% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 30 g in 1 tube.
What NDC number is used to bill for this package of Nystatin 100000 [USP'U]/g Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystatin 100000 [USP'U]/g 45802-0059-11 Padagis 1 tube $0.151 AT Availability likely save 36%
Nystatin 100000 [USP'U]/g 51672-1289-01 Sun 1 tube $0.198 AT Availability likely save 17%
Nystatin 100000 [USP'U]/g 59651-0907-14 Aurobindo 1 tube $0.198 AT Availability likely save 17%
Nystatin 100000 [USP'U]/g 00472-0166-15 Actavis 1 tube $0.233 AT Availability likely save 2%
Nystatin 100000 [USP'U]/g 00713-0686-15 Cosette 1 tube $0.233 AT Availability likely save 2%
Nystatin 100000 U/g 13668-0534-01 Torrent 15 g $0.233 AT Availability likely save 2%
Nystatin 100000 1/g 33342-0481-15 Macleods 1 tube $0.233 AT Availability likely save 2%
Nystatin 100000 U/g 72578-0089-01 Viona 15 g $0.233 AT Availability likely save 2%
Nystatin 100000 [USP'U]/gthis 45802-0048-11 Padagis 1 tube $0.238 AT Availability likely —
Nystatin 100000 [USP'U]/g 69315-0307-15 Leading 1 tube $0.334 AT FDA listed +41%
Nystatin 100000 U/g 50090-5845-00 A-S 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 63187-0464-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 63629-2515-01 Bryant 30 g — AT FDA listed —
Nystatin 100000 U/g 63629-2516-01 Bryant 15 g — AT FDA listed —
Nystatin 100000 U/g 70771-1357-01 Zydus 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 71205-0437-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 72162-2007-02 Bryant 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 72162-2333-02 Bryant 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 63187-0703-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 63187-0847-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 50090-2854-00 A-S 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 72162-1385-02 Bryant 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 68071-4293-03 NuCare 30 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 71335-2830-01 Bryant 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 72162-2496-02 Bryant 1 tube — AT FDA listed —
Mycostatin 100000 [USP'U]/g 72189-0408-15 Direct_Rx 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 63629-8695-01 Bryant 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 50090-2763-00 A-S 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 63629-8694-01 Bryant 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 66267-0952-30 NuCare 30 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 66267-0953-15 NuCare 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 68071-2556-05 NuCare 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 50090-3772-00 A-S 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 50090-3799-00 A-S 1 tube — AT FDA listed —
Nystatin 100000 [USP'U]/g 68788-4099-01 Preferred 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Sep 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS US LLC
FDA applicationANDA062472 (ANDA)
Labeler code45802
First marketedSep 2006
Product typeHuman Prescription Drug
Portfolio175 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 26 words ▾

INDICATIONS AND USAGE Nystatin Ointment USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida [Monilia] albicans and other Candida species.

⏱️ Dosage and Administration 64 words ▾

DOSAGE AND ADMINISTRATION Nystatin Ointment USP should be applied liberally to affected areas twice a day or as indicated until healing is complete. Nystatin cream is usually preferred to nystatin ointment in candidiasis involving intertriginous areas; very moist lesions, however, are best treated with nystatin topical powder. This preparation does not stain skin or mucous membranes and provides a simple, convenient means of treatment.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS Nystatin Ointment USP is contraindicated in patients with a history of hypersensitivity to any of its components.

🤒 Adverse Reactions 34 words ▾

ADVERSE REACTIONS Nystatin Ointment USP is virtually non-toxic and nonsensitizing and is well tolerated by all age groups including debilitated infants, even on prolonged administration. If irritation on topical application should occur, discontinue medication.

🧬 Clinical Pharmacology 139 words ▾

CLINICAL PHARMACOLOGY Nystatin is an antifungal antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It probably acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is a polyene antibiotic that is obtained from Streptomyces noursei , and is the first well tolerated antifungal antibiotic of dependable efficacy for the treatment of cutaneous, oral and intestinal infections caused by Candida [Monilia] albicans and other Candida species.

It exhibits no appreciable activity against bacteria. Nystatin Ointment USP provides specific therapy for all localized forms of candidiasis. Symptomatic relief is rapid, often occurring within 24 to 72 hours after the initiation of treatment.

Cure is effected both clinically and mycologically in most cases of localized candidiasis.

📦 How Supplied / Storage and Handling 54 words ▾

HOW SUPPLIED Nystatin Ointment USP (100,000 USP Nystatin Units per gram) is a yellow ointment available as follows: 15 g tube (NDC 45802- 048 -35) 30 g tube (NDC 45802- 048 -11) STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Manufactured by Padagis ® Yeruham, Israel www.padagis.com Rev 01-23 7K600 RC PH1

📦 Storage and Handling 22 words ▾

STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Manufactured by Padagis ® Yeruham, Israel www.padagis.com Rev 01-23 7K600 RC PH1

📋 Description 45 words ▾

DESCRIPTION Nystatin Ointment USP for topical use only, contains 100,000 USP Nystatin units per gram, in an ointment base of light mineral oil and white petrolatum. The structural formula is as follows: Molecular Weight 926.13 Molecular Formula C 47 H 75 NO 17 structural formula

⚠️ Precautions 24 words ▾

PRECAUTIONS Should a reaction of hypersensitivity occur, the drug should be immediately withdrawn and appropriate measures taken. This preparation is not for ophthalmic use.

📄 Package Label / Principal Display Panel 48 words ▾

Principal Display Panel NDC 45802-048-35 Rx Only Nystatin Ointment USP (100,000 USP Nystatin Units) NET WT 30 g The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. Nystatin Ointment USP carton serialization-template.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
20.8K
Units reimbursed last 4 qtrs
688.8K
Gross reimbursed last 4 qtrs
$331.5K
Avg / prescription
$15.94
Avg / unit
$0.4813
Latest quarter Q1 2026
5.8KRx
Medicaid pays / g
$0.4813
gross reimbursed
vs
NADAC / g
$0.2375
acquisition cost
=
Spread
+$0.2438
+103% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
42% FFS 58% MCO
Fee-for-service · 8,677 Rx Managed care · 12,126 Rx
State Medicaid map
Alaska: 9,233 units · 1,260 per 100k residents AK Maine: no data reported ME Washington: 18,052 units · 231 per 100k residents WA Idaho: 420 units · 21.4 per 100k residents ID Montana: 360 units · 31.8 per 100k residents MT North Dakota: no data reported ND Minnesota: 4,230 units · 73.7 per 100k residents MN Wisconsin: 7,958 units · 135 per 100k residents WI Michigan: 28,974 units · 289 per 100k residents MI New York: 110,810 units · 566 per 100k residents NY Vermont: no data reported VT New Hampshire: 1,710 units · 122 per 100k residents NH Oregon: 8,760 units · 207 per 100k residents OR Nevada: 3,330 units · 104 per 100k residents NV Wyoming: 960 units · 164 per 100k residents WY South Dakota: 5,947 units · 647 per 100k residents SD Iowa: 6,330 units · 197 per 100k residents IA Illinois: 6,195 units · 49.4 per 100k residents IL Indiana: 7,505 units · 109 per 100k residents IN Ohio: 43,935 units · 373 per 100k residents OH Pennsylvania: 30,800 units · 238 per 100k residents PA New Jersey: 4,864 units · 52.4 per 100k residents NJ Massachusetts: 2,880 units · 41.1 per 100k residents MA California: 62,926 units · 161 per 100k residents CA Utah: 6,270 units · 183 per 100k residents UT Colorado: 17,805 units · 303 per 100k residents CO Nebraska: 4,730 units · 239 per 100k residents NE Missouri: 7,114 units · 115 per 100k residents MO Kentucky: 30,710 units · 679 per 100k residents KY West Virginia: 6,420 units · 363 per 100k residents WV Virginia: 17,885 units · 205 per 100k residents VA Maryland: 28,011 units · 453 per 100k residents MD Connecticut: 2,633 units · 72.8 per 100k residents CT Rhode Island: no data reported RI Arizona: 14,580 units · 196 per 100k residents AZ New Mexico: 1,980 units · 93.7 per 100k residents NM Kansas: 5,790 units · 197 per 100k residents KS Arkansas: 5,220 units · 170 per 100k residents AR Tennessee: 16,215 units · 228 per 100k residents TN North Carolina: 26,692 units · 246 per 100k residents NC South Carolina: 5,760 units · 107 per 100k residents SC Delaware: 4,710 units · 457 per 100k residents DE Oklahoma: 2,295 units · 56.6 per 100k residents OK Louisiana: 30,645 units · 670 per 100k residents LA Mississippi: 7,710 units · 262 per 100k residents MS Alabama: 8,205 units · 161 per 100k residents AL Georgia: 22,530 units · 204 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 35,865 units · 118 per 100k residents TX Florida: 9,504 units · 42.0 per 100k residents FL
Units reimbursed · per 100k residents
21.41,260
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Alaska 1,260 /100k
2 Kentucky 679 /100k
3 Louisiana 670 /100k
4 South Dakota 647 /100k
5 New York 566 /100k
6 Delaware 457 /100k
7 Maryland 453 /100k
8 Ohio 373 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page45802-0048-11 20,803 Rx · $331,546
1 tube45802-0048-35 13,610 Rx · $198,848
Drug total (last 4 qtrs): 34,413 Rx · 1,027,894 units · $530,394 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nystatin — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nystatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.29M
Claims incl. refills
853.7K
Beneficiaries
614.3K
Spend / beneficiary
$26.52
Spend / claim
$19.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 45802-0046-11 · Padagis 45802-0049-35 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.